Courtesy of The Joint Blog
For the study, researchers “investigated the effect of a standardized Cannabis sativa extract with high content of cannabidiol (CBD), here named CBD BDS, i.e. CBD botanical drug substance, on colorectal cancer cell proliferation and in experimental models of colon cancer in vivo.”
While conducting the study, it was found that; “CBD reduced cell proliferation in tumoral, but not in healthy, cells. In vivo, CBD reduced AOM-induced preneoplastic lesions and polyps as well as tumour growth in the xenograft model of colon cancer.”
Researchers conclude that “CBD attenuates colon carcinogenesis and inhibits colorectal cancer cell proliferation via CB1 and CB2 receptor activation. The results may have some clinical relevance for the use of Cannabis-based medicines in cancer patients.”
The study, which was conducted by researchers at the University of Naples Federico II in Italy and the University of Aberdeen in the United Kingdom, can be found by clicking here.